Cipher Gene

Cipher Gene is a Chinese precision-medicine and genomic diagnostics company founded in 2015 and headquartered in Chengdu, Sichuan. Its core business spans genetic and rare disease screening and auxiliary diagnosis, three-level prevention and control of birth defects, translational medicine, and drug development services. The company positions itself as a leader in China's genetic disease diagnosis and treatment field, aiming to become a global leader in integrated precision prevention, control, diagnosis, and treatment of genetic diseases. Cipher Gene serves hospitals, clinical research institutions, and families affected by genetic conditions. According to its corporate profile, it provides precision medical services to more than 600 medical and scientific research institutions at home and abroad, supported by big data and artificial intelligence capabilities. Its service model is organized around three pillars: prevention and control (carrier screening for couples of childbearing age, prenatal and neonatal testing), diagnosis (comprehensive genetic testing for children with genetic diseases), and translational medicine services that bridge clinical practice and scientific research. On the product side, Cipher Gene offers next-generation sequencing (NGS) solutions including an enhanced whole exome sequencing product for genetic diseases branded iWES, whole genome sequencing (WGS), and a range of special inspection products tailored to specific disease mechanisms. The company also provides translational medicine services and operates a high-throughput drug screening R&D center. The company reports an interdisciplinary professional R&D team, more than 100 high-level international academic papers published, and more than 200 intellectual property rights including patents. It states that it holds a third-party medical laboratory certified by the College of American Pathologists (CAP) and clinical molecular genetics qualifications from the American Board of Medical Genetics and Genomics (ABMGG). Cipher Gene is headquartered in Chengdu, with R&D centers in Beijing and production and operation centers, medical laboratories, and drug screening facilities in the Yangtze River Delta region. It is a private company and does not appear to be publicly listed.

Cipher Gene was founded in 2015 in China, emerging during a period of rapid growth in the country's genomic medicine and precision diagnostics sector. The company built its business around genetic disease and rare disease screening and auxiliary diagnosis, three-level prevention and control of birth defects, translational medicine, and drug development services. From its base in Chengdu, Sichuan, it expanded its footprint to include R&D centers in Beijing and production and operation centers, medical laboratories, and a high-throughput drug screening R&D center in the Yangtze River Delta region. Over its development, Cipher Gene positioned itself as a specialist in the clinical genetics space, serving hospitals and research institutions. Its corporate profile states that it now provides precision medical services to more than 600 medical and scientific research institutions at home and abroad, leveraging big data and artificial intelligence. The company reports an interdisciplinary R&D team, more than 100 high-level international academic papers, and more than 200 intellectual property rights including patents. Cipher Gene has pursued international quality standards, stating that it holds a third-party medical laboratory certified by the College of American Pathologists (CAP) and clinical molecular genetics qualifications from the American Board of Medical Genetics and Genomics (ABMGG). It has also developed its own testing technologies and products, including the iWES enhanced whole exome sequencing solution and whole genome sequencing services. The company has engaged in multicenter clinical research, such as an adult epilepsy whole exome sequencing research project initiated by Xiangya Hospital of Central South University, and has conducted public welfare activities including an International Epilepsy Caring Day micro-film. As of the available evidence, Cipher Gene remains an active private company focused on the Chinese market.

• 2015

  Cipher Gene founded in China.

• Headquartered in Chengdu, with R&D centers in Beijing and operations in the Yangtze River Delta region.

• Provides precision medical services to more than 600 medical and scientific research institutions at home and abroad.

• Published more than 100 high-level international academic papers and obtained more than 200 intellectual property rights.

• Holds CAP-certified third-party medical laboratory and ABMGG clinical molecular genetics qualifications.

• Participated in adult epilepsy WES multicenter research project initiated by Xiangya Hospital of Central South University.

Leading enterprise in China's genetic disease diagnosis and treatment field, aiming to become a global leader in integrated precision prevention, control, diagnosis, and treatment of genetic diseases.

• iWES (Enhanced Whole Exome Sequencing for Genetic Diseases)

  Extended testing based on WES, described as achieving precision, speed, and economy.

• Whole Genome Sequencing (WGS)

  Maximizes the value of a tube of blood, capturing all variants in one go.

• Special Inspection Products

  Tailored to the disease, selecting different detection methods based on pathogenic mechanisms to improve accuracy and comprehensiveness.

• Translational Medicine Service

  Functional studies on clinical samples bridging clinical practice and research.

1. 1Cipher Gene official website homepageciphergene.com
2. 2About CipherGeneciphergene.com
3. 3Products and Servicesciphergene.com
4. 4About CipherGeneciphergene.com
5. 5Wikidata: Cipher Gene (China)wikidata.org